What is the current stock price of Celcuity Inc. (CELC)?

As of the latest market data, Celcuity Inc. (CELC) is trading at $117.14. The stock has seen a loss of -6.02% today.

Does Celcuity Inc. (CELC) pay a dividend?

Based on current data, Celcuity Inc. does not have a confirmed active dividend policy.

What is the market cap of Celcuity Inc.?

The current market capitalization of Celcuity Inc. (CELC) is approximately unavailable.

CELC

Celcuity Inc.·Healthcare

117.14

6.017%(−7.50)

Market Closed

125.00

6.710%(+7.86)

After Hours

Last Updated: — ET

52W L: $9.0252W H: $125.00

CELC NEWS

defenseworld.net

3d ago

Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC

Nisa Investment Advisors LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ: CELC) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508 shares of the company's stock after selling 15,119 shares during the period. Nisa

fool.com

Mar 26

Why Celcuity Stock Popped Today

It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.

seekingalpha.com

Mar 25

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 25

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.

globenewswire.com

Mar 18

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m.

defenseworld.net

Mar 16

Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Celcuity, Inc. (NASDAQ: CELC - Get Free Report) have received an average rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the

Company Profile

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-09-20

Beta

0.42

Websitewww.celcuity.com↗